Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index

Phase 1

Recruiting

• Conditions: Renal Protection
• Interventions: Drug: placebo drug; Drug: Atorvastatin 40 Mg Oral Tablet

• Registration Number: NCT05946122
• Lead Sponsor: Minia University

Brief Summary

Offering renal protection in systemic inflammatory response syndrome by atorvastatin

Detailed Description

Not available

Study Timeline

• Study Start: 2023-05-30
• Study First Submitted: 2023-06-27
• Status Verified: 2023-07
• Study First Submitted QC: 2023-07-06
• Last Update Submitted: 2023-07-06
• Study First Posted: 2023-07-14
• Last Update Posted: 2023-07-14
• Primary Completion: 2023-12-12
• Study Completion: 2023-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 106

Inclusion Criteria

• Patients ( male and female) with systemic inflammatory response ( total leucocytic count >12,000 mm3'. temperature >38 C, Heart rate >90 b/min and respiratory rate>20 cycle).

Exclusion Criteria

• Hemodynamic instability
• Pre-admission chronic kidney disease.
• Intra-vascular coagulopathy
• Patients with myopathy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
control group	placebo drug	-
Active ( Ator) group	Atorvastatin 40 Mg Oral Tablet	-

Primary Outcome Measures

Name	Time	Method
Acute kidney injury	one week	incidence or acute kidney injury

Secondary Outcome Measures

Name	Time	Method
renal resistive vascular index	one week	renal resistive index
APACHE score ( acute physiology and chronic health evaluation)	one week	acute physiology and chronic health evaluation, values below 40 are considered normal while values between 41 and 71 are considered abnormal .
length of ICU stay	two weeks	days of ICU admission

Trial Locations

Locations (1)

Mina Maher Raouf; 🇪🇬 Minia, Minia University, Egypt